Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bubba Kush + cannabidiol is a combination of the Indica-dominant cannabis strain Bubba Kush, which is characterized by high concentrations of delta-9-tetrahydrocannabinol (THC), and supplemental purified cannabidiol (CBD). This combination is primarily utilized in clinical research to investigate the "entourage effect" and the ability of CBD to modulate the pharmacological profile of THC. THC acts as a partial agonist at the G protein-coupled cannabinoid receptors CB1 and CB2, mediating analgesic, sedative, and psychoactive effects. CBD acts as a non-competitive negative allosteric modulator of the CB1 receptor, which may reduce the ceiling of THC's psychoactive impact, and as an agonist at the 5-HT1A serotonin receptor, potentially providing anxiolytic benefits. The combination is often studied for its potential to treat chronic pain, anxiety, and sleep disorders while minimizing the cognitive impairment and tachycardia associated with high-THC strains.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bubba Kush + cannabidiol.